Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease.
chronic lymphocytic leukemia
severe chronic kidney disease
tumor lysis syndrome
venetoclax
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
14
12
2021
accepted:
25
03
2022
entrez:
20
4
2022
pubmed:
21
4
2022
medline:
21
4
2022
Statut:
epublish
Résumé
Venetoclax is a promising new drug for relapsed or refractory chronic lymphocytic leukemia (CLL). However, venetoclax use had not been reported in severe chronic kidney disease (CKD) patients. We report the first case of relapsed CLL in a severe CKD patient that was successfully treated with venetoclax.
Identifiants
pubmed: 35441018
doi: 10.1002/ccr3.5735
pii: CCR35735
pmc: PMC9010727
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e05735Informations de copyright
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare no potential conflicts of interest regarding the publication of this study.
Références
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Kidney Int. 2005 Jun;67(6):2089-100
pubmed: 15882252
Haematologica. 2020 Mar;105(3):e141-e143
pubmed: 31753932
Oncologist. 2017 Nov;22(11):1283-1291
pubmed: 28851760
Clin Case Rep. 2022 Apr 14;10(4):e05735
pubmed: 35441018
J Clin Pharmacol. 2017 Apr;57(4):484-492
pubmed: 27558232
Clin Pharmacokinet. 2019 Aug;58(8):1091-1100
pubmed: 30949874